Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

doi:10.1126/science.abf4058

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.

Science (New York, N.Y.) - 26 Feb 2021

White Kris M, Rosales Romel, Yildiz Soner, Kehrer Thomas, Miorin Lisa, Moreno Elena, Jangra Sonia, Uccellini Melissa B, Rathnasinghe Raveen, Coughlan Lynda, Martinez-Romero Carles, Batra Jyoti, Rojc Ajda, Bouhaddou Mehdi, Fabius Jacqueline M, Obernier Kirsten, Dejosez Marion, Guillén María José, Losada Alejandro, Avilés Pablo, Schotsaert Michael, Zwaka Thomas, Vignuzzi Marco, Shokat Kevan M, Krogan Nevan J, García-Sastre Adolfo

Abstract excerpt

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Monophosphate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alanine

Share to Coronavirus Nucleocapsid Proteins

Share to COVID-19 Drug Treatment

Share to Depsipeptides

Share to Drug Evaluation, Preclinical

Share to Peptide Elongation Factor 1

Share to Peptides, Cyclic

Source

Open in PubMed Open full text

Identifiers

PMID: 33495306
DOI: 10.1126/science.abf4058
PMCID: PMC7963220

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.PMID 33495306Read ↗

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variantSemantic proximity Read ↗

Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in miceSemantic proximity Read ↗

Pyronaridine Protects Against SARS-CoV-2 in MouseSemantic proximity Read ↗

Viral target and metabolism‐based rationale for combined use of recently authorized small molecule COVID‐19 medicines: Molnupiravir, nirmatrelvir, and remdesivirSemantic proximity Read ↗

Anthracyclines inhibit SARS-CoV-2 infectionSemantic proximity Read ↗

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19Semantic proximity Read ↗

Orally administered epeleuton inhibits SARS-CoV-2 viral load, replication and pathology in the Syrian Hamster modelSemantic proximity Read ↗

RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug DiscoverySemantic proximity Read ↗

Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an M pro Protease Inhibitor for Treatment of SARS-CoV-2Semantic proximity Read ↗

A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial CellsSemantic proximity Read ↗

Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibitionSemantic proximity Read ↗

CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.